Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (PAHC) delivers essential animal health solutions and mineral nutrition products for global food production systems. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and operational milestones.
Access official press releases and curated analysis covering PAHC's strategic initiatives across its three core segments: Animal Health pharmaceuticals, Mineral Nutrition supplements, and Performance Products. Track updates including earnings reports, product innovations, regulatory developments, and partnership announcements that impact the livestock health sector.
This centralized resource enables stakeholders to monitor PAHC's responses to industry challenges and opportunities, from disease prevention advancements to nutritional science breakthroughs. Content is organized for efficient scanning while maintaining technical accuracy for veterinary professionals and investors alike.
Bookmark this page for direct access to PAHC's latest corporate communications and market-moving updates. Combine regular monitoring with historical context to inform your analysis of this animal health sector leader.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to announce its second quarter financial results on February 9, 2022, after market close. A conference call and webcast will follow on February 10, 2022, at 9:00 AM ET. Interested parties can join via the company's investor relations website or by calling provided numbers. Phibro develops and supplies a range of animal health products, promoting sustainable livestock management and food production. For more details, visit www.pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 4th Annual Evercore ISI Virtual Conference on December 1, 2021, at 8:00 AM ET. Chief Financial Officer Damian Finio and Executive Vice President Daniel Bendheim will present to financial analysts and investors. Participants can access the live audio presentation on the Phibro Investor Relations Website, and a replay will be archived for later listening. Phibro is a global developer and supplier of animal health and mineral nutrition products aimed at supporting sustainable food production.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q1 financial results for the period ending September 30, 2021. Net sales increased by 10% to $215 million, while net income dropped 47% to $7 million. Diluted EPS fell by 47% to $0.16. The company raised its fiscal year net sales guidance to $860-$890 million, citing strong product demand, especially in nutritional specialties and vaccines, despite challenges from increased costs. Gross profit margins decreased to 30.1%. The outlook includes further price adjustments to offset rising freight costs.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of
Phibro Animal Health Corporation (NASDAQ: PAHC) will release its first quarter financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for November 3, 2021, at 9:00 AM ET. Investors can access the presentation through the company’s investor relations website. This event is expected to provide key insights into the company's financial performance and future guidance, an important aspect for stakeholders.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 30th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2021, at 4:20 PM ET. Key executives, including Chairman
Phibro Animal Health Corporation (Nasdaq: PAHC) reported strong Q4 and full-year results for fiscal year 2021, with net sales of $220 million in Q4, up 19% year-over-year, and $833 million for the year, an increase of 4%. Net income surged to $17 million in Q4, reflecting a 203% increase, and $54 million for the year, a 62% rise. Diluted EPS also rose to $0.42 for Q4 and $1.34 for the full year. Guidance for FY 2022 projects net sales of $840-$870 million and net income of $45-$47 million.
Phibro Animal Health Corporation (Nasdaq: PAHC) will participate in the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 9:30 AM ET. Chairman and CEO Jack Bendheim, CFO Damian Finio, and EVP Daniel Bendheim will address analysts and investors during the session. The live audio presentation can be accessed on the company’s Investor Relations website, with a replay also available. Phibro focuses on developing a wide range of animal health and mineral nutrition products for livestock.
Phibro Animal Health Corporation (Nasdaq:PAHC) will participate in the Bank of America Virtual Global Healthcare Conference on September 15, 2021, at 9:10 AM ET. Chief Financial Officer Damian Finio will present to financial analysts and investors, with a live audio available on the company's Investor Relations website. A replay will also be archived for future access. Phibro is a global developer and supplier of animal health and nutrition products, helping produce healthy food sustainably.
Phibro Animal Health Corporation (Nasdaq:PAHC) will announce its fourth quarter and fiscal year 2021 financial results on August 25, 2021, post-market. A conference call will occur on August 26, 2021, at 9:00 AM ET, where interested parties can join via phone or webcast. The company focuses on developing and supplying animal health and mineral nutrition products for livestock, aiming to enhance food production while conserving natural resources. Further details are available on their investor website.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
